• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: July 14, 2025

Key Takeaways

  • Melanoma survivors advocate for early detection, routine skin exams, and public education to improve survival rates.
  • Boehringer Ingelheim and LEO Pharma collaborate to advance and commercialize Spesolimab globally.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Learning From Patient Experiences of Melanoma

Melanoma survivors share their diagnoses and advocate for early detection, routine skin exams, and public education to save lives.

Boehringer Ingleheim, LEO Pharma Announce Partnership to Advance Spesolimab in GPP and Beyond

The pharmaceutical companies announced an exclusive global license and transfer agreement for the advancement and commercialization of Spevigo.

Deuruxolitinib Launches in US for Treatment of Severe Alopecia Areata

Sun Pharmaceuticals has launched deuruxolitinib (Leqselvi) in the US, offering a new treatment for adults with severe alopecia areata.

French Survey Reveals Gaps in CHE Severity Assessment

A national Delphi survey reveals critical insights into CHE management in France, highlighting the need for standardized assessment and guidelines.

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Both regulatory-approved and pipeline treatments for moderate to severe HS demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.